Key Highlights
- Pharmaceutical giant Eli Lilly is pursuing a deal to purchase Kelonia Therapeutics for more than $2 billion, according to Wall Street Journal sources
- An announcement could come as soon as Monday, with additional milestone-based compensation possible
- Kelonia specializes in innovative CAR-T immunotherapy targeting multiple myeloma, a type of blood cancer
- The Massachusetts-based startup has secured approximately $60 million in funding and carried a valuation slightly above $100 million in 2022
- This acquisition would strengthen Lilly’s cancer treatment portfolio as the company diversifies beyond its successful obesity medications
Pharmaceutical powerhouse Eli Lilly is pursuing a significant acquisition of Massachusetts-based Kelonia Therapeutics, with sources indicating a price exceeding $2 billion, the Wall Street Journal reported over the weekend. While an announcement may come within days, sources caution that negotiations remain ongoing and could collapse.
According to individuals briefed on the discussions, the agreement may incorporate performance-based payments contingent upon Kelonia achieving specific clinical and regulatory benchmarks.
Shares of LLY gained approximately 2.55% following the disclosure.
Kelonia operates as a clinical-stage biopharmaceutical company specializing in CAR-T cellular immunotherapy — an innovative cancer treatment method that engineers a patient’s immune cells to identify and eliminate malignant cells.
The biotech’s primary therapeutic target is multiple myeloma, a blood cancer affecting plasma cells. Kelonia’s technology seeks to streamline CAR-T administration by eliminating the need for preparatory chemotherapy and reducing the complex cellular engineering processes traditionally required.
This represents a significant advancement in the CAR-T field, where treatment accessibility and manufacturing complexity have historically limited broader adoption.
Kelonia has secured nearly $60 million in total funding since inception. Its 2022 valuation stood marginally above $100 million — suggesting the reported $2 billion-plus offer represents a substantial premium.
Neither Eli Lilly nor Kelonia provided comments to Reuters inquiries made outside standard business hours.
Expanding Cancer Treatment Capabilities
Lilly maintains an established presence in oncology therapeutics. Current cancer medications include Jaypirca and the breast cancer treatment Verzenio, complemented by multiple investigational compounds in development.
Acquiring Kelonia would significantly expand Lilly’s position in hematologic malignancies, representing one of oncology’s most dynamic growth segments.
This transaction aligns with recent strategic moves. Lilly has pursued aggressive business development activities, supported by substantial revenue from blockbuster medications Zepbound for weight management and diabetes drug Mounjaro.
Earlier this year in February, Lilly announced plans to acquire Orna Therapeutics in a transaction valued at up to $2.4 billion. The Kelonia deal would mark another substantial investment within months.
Strategic Diversification Continues
Lilly has articulated clear intentions to expand its therapeutic portfolio beyond metabolic disease. The pharmaceutical company has been pursuing opportunities in inflammatory bowel conditions, ophthalmology, oncology, and genetic medicine through strategic acquisitions and collaborative partnerships.
CAR-T immunotherapy aligns perfectly with this expansion strategy. The technology has demonstrated substantial clinical efficacy against hematologic cancers, with multiple therapies already receiving regulatory approval — though manufacturing scalability and treatment costs continue presenting industry-wide obstacles.
Kelonia’s streamlined treatment approach represents its primary competitive advantage. Successfully delivering clinical outcomes while reducing operational complexity would provide significant market differentiation worth substantial investment.
Lilly has not officially confirmed the transaction. Wall Street Journal sources indicated negotiations could still terminate before any formal announcement.
LLY shares traded approximately 2.55% higher following the weekend report.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
